Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Frequently asked questions
What sector does Kyverna Therapeutics, Inc. Common Stock (KYTX) operate in?
Kyverna Therapeutics, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Kyverna Therapeutics, Inc. Common Stock (KYTX) current stock price?
As of the latest data, Kyverna Therapeutics, Inc. Common Stock stock price is $5.27, with a previous close of $5.39. Kyverna Therapeutics, Inc. Common Stock lost -$0.12 in the last trading session, representing a -2.23% loss.
What is Kyverna Therapeutics, Inc. Common Stock (KYTX) current market capitalization?
Kyverna Therapeutics, Inc. Common Stock market cap is approximately 325.91 million.
What is Kyverna Therapeutics, Inc. Common Stock (KYTX) Earnings Per Share (EPS)?
The trailing EPS is -$2.89, and the forward EPS is -$3.17.
What is Kyverna Therapeutics, Inc. Common Stock (KYTX) EBITDA?
Kyverna Therapeutics, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -37.21 million.
Does Kyverna Therapeutics, Inc. Common Stock (KYTX) pay dividends?
No. Kyverna Therapeutics, Inc. Common Stock does not pay a dividend.
When is Kyverna Therapeutics, Inc. Common Stock (KYTX) next earnings report?
Kyverna Therapeutics, Inc. Common Stock is expected to release its next earnings report on September 30, 2026.
What is Kyverna Therapeutics, Inc. Common Stock (KYTX) beta (volatility) score?
Kyverna Therapeutics, Inc. Common Stock has a beta of 1.990, suggesting it is more volatile than the market.
